期刊文献+

腹膜透析与血液透析患者肾性贫血治疗效果比较 被引量:4

Curative effectiveness of renal anemia during peritoneal dialysis vs. hemodialysis
下载PDF
导出
摘要 目的比较腹膜透析(peritoneal dialysis,PD)与血液透析(hemodialysis,HD)患者肾性贫血的治疗效果。方法选择尿毒症行肾脏替代治疗患者90例,其中腹膜透析患者41例,血液透析患者49例。患者入组前1个月内均未行肾脏替代治疗、未使用促红细胞生成素(erythropoietin,EPO)、无失血;在肾脏替代治疗开始时加用EPO,比较腹膜透析组(PD组)和血液透析组(HD组)患者治疗前、治疗后第1、2、3个月血红蛋白(hemoglobin,Hb)的变化,以及PD组与HD组治疗后3个月超敏C反应蛋白(high sensitivity C reactive protein,hs—CRP)、血白蛋白(albumin,Alb)、尿素清除指数(Kt/V)的差异。结果治疗前2组的Hb值无统计学差异(P〉O.05或P〉0.01),治疗后第3个月2组的hs-CRP、Alb、Kt/V值无统计学差异(P〉0.05或P〉0.01)。透析治疗前后比较,PD组治疗后第1、2、3个月的Hb值均较治疗前升高(P〈0.05或P〈0.01),且治疗后第3个月〉第2个月〉第1个月;HD组治疗后第1、2、3个月的Hb值均较治疗前升高(P〈0.05或P〈0.01),且治疗后第3个月〉第2个月〉第1个月。PD组治疗后第1、2、3个月EPO的Hb值分别高于HD组,差异具有显著性(P〈0.01)。结论肾脏替代治疗、使用EPO可有效纠正尿毒症患者的肾I生贫血,PD患者使用EP0更有利于肾陛贫血的纠正。 Objective To compare the curative effectiveness of renal anemia during peritoneal dialysis (PD) vs. hemodialysis (HD). Methods A total of 90 uremia patients were divided into two groups: PD group (n = 41) and HD group (n = 49). At the beginning of the therapy, the patients were not treated with erythropoietin and had no bleeding. Patients in PDA group and HD group were treated with erythropoietin during the renal replacement therapy. The hemoglobin (Hb) levels both group were determined before, and at first,2nd and 3rd month after treatment. At third month after treat- ment, the high sensitivity C reactive protein (hs-CRP), albumin (Alb), and Kt/V in PD group and HD group were compared. Results There was no difference between the PD group and HD group in Hb levels before treatment. The Hb levels in the PD group and HD group were increased progressively af- ter dialysis for one month, two months and three months (P〈0. 05 or P〈0. 01) as compared with those before treatment. The Hb levels in PD group were significantly higher than in HD group after treatment for one month, two months and three months. There was no difference in hs-CRP, Alb and Kt/V between the PD group and HD group after dialysis for three months. Conclusions Erythropoie- tin can correct anemia in dialysis patients (including PD patients and HD patients). The effect of PD is more significant than that of HD.
出处 《临床肾脏病杂志》 2013年第7期300-303,共4页 Journal Of Clinical Nephrology
基金 江苏省卫生厅面上科研课题(NO:H200834)
关键词 肾眭贫血 腹膜透析 血液透析 促红细胞生成素 Renal anemia Peritoneal dialysis Hemodialysis Erythropoietin
  • 相关文献

参考文献3

二级参考文献36

  • 1牛建英,袁瑾,罗丽红,张琦,范伟峰,顾勇.血红蛋白浓度对维持性血液透析患者再入院的影响[J].中国中西医结合肾病杂志,2006,7(9):522-523. 被引量:12
  • 2Scigalla P,Bonzel KE,Bulla M,et al.Therapy of renal anemlia with recombinant human erythropoietin in chidren with endstage real disease.Contrib Nephrol,1989,76:227-240.
  • 3刘力生,龚兰生.1999年中国高血压防治指南(试行本).中国高血压防治指南起草委员会,1999.8-19.
  • 4Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 2004,44:94-111.
  • 5Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol, 2006,1 : 1205-1210.
  • 6Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol, 2009,20:479-487.
  • 7Szeto CC, Kwan BC, Chow KM, et al. Haemoglobin variability in Chinese pre-dialysis CKD patients not receiving erythropoietin. Nephrol Dial Transplant, 2011,26:2919-2124.
  • 8Betas JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int, 2003,64 : 1514- 1521.
  • 9Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis, 2003, 41 : ! 11-124.
  • 10Collins A J, Kasiske B, Herzog C,et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis, 2007, 49 ( 1 Suppl 1 ) :A6-7, S1-296.

共引文献26

同被引文献44

  • 1赖玮婧,刘芳.2012年KDIGO慢性肾脏疾病血压管理临床实践指南解读[J].中国医学前沿杂志(电子版),2013,5(6):69-73. 被引量:15
  • 2李丹(综述),赵学智(审校).肾性贫血与促红细胞生成素[J].国际泌尿系统杂志,2007,27(2):277-281. 被引量:14
  • 3NKF-KDIGO guideline development staff. KDIGO Clinical practice guideline for anemia in chronic kidney disease: Feb, 2012.
  • 4Barsoum RS. Overview: end-stage renal disease in the develo ping world[J]. Artif Organs, 2002, 26(9): 737-746.
  • 5Tsubakihara Y, Nishi S, Akiba T, et al. 2008 Japanese Socie- ty for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease[J]. Ther Apher Dial, 2010, 14(3): 240-275.
  • 6Krapf R, HulterHN. Arterial hypertension induced by eryth- ropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am SocNephrol, 2009, 4(2): 470-480.
  • 7Kuriyama S, Tomonari H, Tokudome G, et al. Association of angiotensinogen gene polymorphism with erythropoietin-in- ducedhypertension: a preliminary report[J]. Hypertens Res, 2001, 24(5):501-505.
  • 8SchiffrinEL. Vascularendothelin in hypertension[J]. VasculP- harmacol, 2005, 43(1): 19-29.
  • 9Lebel M, Moreau V, Grose JH, et al. Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy[J]. ClinNephrol, 1998, 49(5): 313-318.
  • 10Ioka T, Tsuruoka S, Ito C, et al. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients[J]. ClinPharmacolTher, 2009, 86(2): 154-159.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部